Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide

European Journal of Clinical Pharmacology

Volumn 60, Issue 2, 2004, Pages 109-114

  Bidstrup, Tanja Busk ^a   Stilling, Nicolaj ^a   Damkier, Per ^b   Scharling, Birgitte ^c   Thomsen, Mikael Søndergård ^d   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d Prosidion Limited   (United Kingdom)

Author keywords

Interaction; Repaglinide; Rifampicin

Indexed keywords

REPAGLINIDE; RIFAMPICIN;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES; QUINIDINE; RIFAMPIN; TIME FACTORS;

EID: 2442455598     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0746-z     Document Type: Article

References (26)

1. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J (1995) Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 38:1025-1032
2. Nattrass M, Lauritzen T (2000) Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes? Int J Obes 24:S21-S31
3. 14C-repaglinide during repaglinide multiple dosing. Eur J Clin Pharmacol 55:521-525
4. Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56:305-314
5. Hatorp V, Hansen KT, Thomsen MK (2003) Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 43:649-660
6. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT (2000) Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 68:495-500
7. Damkier P, Brosen K (2000) Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clin Pharmacol Ther 68:199-209
8. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE (1999) Morning spot and 24-hour urinary 6β-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 39:487-494
9. 450IIIa induction. Br J Clin Pharmacol 28:373-387
10. Nielsen F, Nielsen KK, Brøsen K (1994) Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine and quinidine N-oxide in plasma and urine by high-performance liquid chromatography. J Chromatogr B 660:103-110
11. Lykkesfeldt J, Loft S, Poulsen HE (1994) Simultaneous determination of urinary free cortisol and 6 beta-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B 660:23-29
12. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242-251
13. Rae JM, Jhonson MD, Lippman ME, Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849-857
14. 450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 302:475-482
15. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347-351
16. Wang J, Neuvonen M, Wen X, Backman JT, Neuvonen PJ (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352-1356
17. 4502C9. Drug Metab Dispos 29:1359-1361
18. 4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 289:31-37
19. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT (2003) Pharmacokinetic interactions with rifampicin - clinical relevance. Clin Pharmacokinet 42:819-850
20. 450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878
21. Glaeser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O, Dent J, Somogyi A, von Richter O, Griese E, Eichelbaum M, Fromm MF (2002) Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin Pharmacol Ther 71:131-140
22. Klose TS, Blaisdell J, Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13:289-295
23. 4503A coordinately up-regulates these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318
24. Fardel O, Lecureur V, Loyer P, Guillouzo A (1995) Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol 49:1255-1260
25. Zong J, Pollack GM (2003) Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exp Ther 306:556-562
26. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ (2003) Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74:380-387